The fundamental disturbance of the parkinsonian gait is without stimulation and with and without a suprathreshold dose of L-dopa. With STN stimulation, there the reduction in walking velocity. This is mainly due to reduction in stride length, while cadence (steps/min) is were increases of almost threefold in mean walking velocity ( 
Introduction
A typical symptom of Parkinson's disease is a short-stepped, relationship is similar in healthy subjects and Parkinson's disease patients, whereas the intercept for stride length is shuffling gait with slow walking velocity and decreased amplitude of the segmental movements. The problem in this reduced (Morris et al., 1998) . This means that Parkinson's disease patients are able to increase their stride length by gait disturbance is the regulation of stride length (Morris et al., 1994a, b) . Healthy subjects achieve an increase in amounts similar to those achieved by healthy subjects for any given increase in cadence, but that the stride length is walking velocity by increasing both stride length and cadence to a similar extent. Cadence regulation is not disturbed in preset at a lower level for the whole stride length-cadence relationship in Parkinson's disease. Furthermore, the usable Parkinson's disease. The slope of the stride length-cadence range of this relationship is reduced, which means that the stimulation according to criteria reported by Limousin and colleagues (Limousin et al., 1998) . The position of the 'break point', i.e. the point at which stride length cannot be increased any more, occurs at a lower cadence. Treatment electrode was checked by intraoperative teleradiography and postoperative MRI. All the implanted electrodes were in the with L-dopa increases stride length and kinematic measures (swing velocity, peak velocity), whereas temporal measures, STN area. The stimulation was monopolar and used only one contact for each of the 16 implanted electrodes. The rate such as cadence, swing duration, double limb support time (both feet in contact with the ground) and, in one study, also (mean Ϯ SD) was 148 Ϯ 24 Hz for the left side and 139 Ϯ 19 Hz for the right, and the voltage 3.0 Ϯ 0.4 V for cadence variability, have been found to be resistant to L-dopa (Blin et al., 1991; O'Sullivan et al., 1998) . Treatment with the left side and 2.8 Ϯ 0.4 V for the right. The pulse width was 60 µs for 15 electrodes and 90 µs for one. All patients L-dopa increases the usable range of the stride length-cadence relationship and also the intercept for stride length (Morris had a clear response to L-dopa. We did not select the patients according to the degree of benefit induced by STN stimulation. et al., 1998) .
Chronic thalamic stimulation has no effect on parkinsonian Consecutive patients who were able to walk off-stimulation/ off-medication and who agreed to travel to Freiburg entered gait (Defebvre et al., 1996) . Bilateral posteroventral pallidotomy results in a twofold increase in stride length the study. Detailed clinical data are given in Table 1 . Five of the patients still required L-dopa after implantation without a change in cadence (Siegel and Metman, 2000) . The efficacy of electrical stimulation of the subthalamic (Table 1) . Additional medication included amantadine in one patient, pergolide in two patients and bromocriptine in three nucleus (STN) in advanced Parkinson's disease has clearly been demonstrated clinically by the use of qualitative scales patients. Additionally, 12 age-matched control subjects, with a mean age of 51.1 Ϯ 9.1 years, were investigated. The study (Limousin et al., 1998; Yokoyama et al., 1999) . However, quantitative assessment of gait in Parkinson's disease with was approved by the ethics committee of the University of Freiburg according to the declaration of Helsinki, and the chronic STN stimulation has not been published. Preliminary reports suggest a tremendous effect of STN stimulation on patients and healthy control subjects gave their written informed consent. walking velocity (Allert et al., 2000; Faist et al., 2000; Krystkowiak et al., 2000; Melnick et al., 2000) . However, results concerning the strategies by which this effect is achieved are divergent. Two of these studies suggest that the
General experimental procedure
The gait analysis and clinical assessment were performed in improvement is due exclusively to an increase in stride length (Faist et al., 2000; Melnick et al., 2000) , similar to what was the gait laboratory of the Department of Neurology and Clinical Neurophysiology of Freiburg University Hospital in found for L-dopa (Blin et al., 1991; Morris et al., 1998; O'Sullivan et al., 1998) . The other two studies report also four conditions: (i) off-stimulation/off-medication (-stim/ -dopa); (ii) on-stimulation/off-medication (ϩstim/-dopa); an increase in cadence (Allert et al., 2000; Krystkowiak et al., 2000) . The questions arise whether changes in measures (iii) off-stimulation/on-medication (-stim/ϩdopa); and (iv) on-stimulation/on-medication (ϩstim/ϩdopa). One experiof gait induced by STN stimulation are different from those induced by pallidotomy or L-dopa and whether the effects of mental session took~1 h for each of the four conditions, including attachment of electrodes and goniometers and L-dopa and STN stimulation are differential or additive. Deep-brain stimulation offers the exceptional possibility of interruptions for rest. Two conditions were performed per day (early morning off-medication, late morning on-medication); studying the same patient with and without 'symptoms' within the same experimental session. The aim of the present 2 days were required per patient for the gait experiments (1 day off-and 1 day on-stimulation). The order of the offstudy was to quantify, in an appropriate crossover design, changes in the gait pattern of Parkinson's disease patients and on-stimulation conditions was randomized; thus, four patients started in the off-stimulation condition and four receiving chronic bilateral STN stimulation in four treatment conditions: with and without STN stimulation and with and patients started in the on-stimulation condition. The stimulation condition was set at least 1 h before the without a suprathreshold dose of L-dopa. Also, a group of healthy age-matched control subjects was investigated. Some experiment by a person independent of the experimenters, who were blinded to the stimulation condition and to the of these results have been published in abstract form (Faist et al., 2000) .
patients. Despite this blinded condition, all patients identified the stimulation condition within a few minutes because of the magnitude of the effect. Before they were assessed off-medication, patients fasted and drugs were withdrawn
Patients and methods
Eight Parkinson's disease patients (three women and five overnight. The assessment on-medication was performed when the patient was fully 'on',~40 min after the men) with a mean age of 48.1 years were investigated. These patients represent a rather young group, with disease onset administration of a suprathreshold dose of 200-300 mg liquid L-dopa and 50-75 mg benserazide (dispersible Madopar) and at 34.8 years compared with the average onset of Parkinson's disease at 55 years. All had been operated at the Grenoble a light breakfast to minimize variability in the absorption of L-dopa and to speed up the absorption of L-dopa. Thus, the University Hospital and received chronic bilateral STN (Tinetti, 1986) . Healthy control subjects performed the experimental instructed to keep their walking velocity constant and at the maximum comfortable speed. For safety reasons, all subjects procedure only once.
were secured with a safety belt without weight support; the belt was suspended from the ceiling to prevent injuries in case of a fall. After 5 min of training with stimulation on,
Gait analysis: recording methods
For the quantitative analysis of gait, subjects walked on a all patients were able to walk freely and comfortably with this system. For gait assessment, at least 3 min of walking self-driven treadmill with separate belts for the right and left feet. Each of the two belts was placed separately over a in a steady state for each of the four conditions was recorded in the crossover design described above. Two patients were force-measuring system (Kistler, Winterthur, Switzerland). Thus, we were able to determine the force exerted on each unable to walk the required 120 stride cycles in the offmedication and off-stimulation conditions; therefore, only belt and to assess heel contact and toe off in the step cycle from the output of four piezo elements fixed at the corners some of the biomechanical measures could be assessed in this single condition. One of these patients had started offof each belt. The left leg can be placed on the right belt and vice versa, especially during fast walking, so that not all stimulation and the other had started on-stimulation, so the crossover design was not spoiled. strides could be determined correctly by the force-measuring system. To determine spatiotemporal measurements for these strides, subjects wore on both feet a specially designed shoe that contained circuit breakers to determine heel strike and
Data analysis
Spatiotemporal and velocity recordings were amplified toe off. We recorded continuously the treadmill velocity and the position of the subject in an anterior or posterior direction (floating input amplifier, bandwidth 3-200 Hz, sensitivity 2 mV/V) and transferred on-line to a computer system on the belt. Angular displacements of the hip, knee and ankle joint of the right leg were measured using laterally placed (IBM-compatible Pentium) via an analogue-digital converter sampling at 500 Hz. The data were analysed off-line with goniometers. To adjust the treadmill velocity to the subject's chosen walking velocity, a closed-loop control system was software developed by our gait laboratory and programmed in LabView, National Instruments, Munich, Germany. The used in which measurement of the subject's position on the treadmill gave the information required. The position was onset of the force signal was used as a trigger for selecting successive stride cycles. Stride duration was defined as the determined by a distance measurement (Headtracker ultrasonic system; Logitech, Fremont, Calif., USA) between duration of the period between two successive impacts of the right leg. Walking velocity, stride and step length, cadence, a fixed emitter placed behind the treadmill and a receiver placed on the subject's back. When the subject tended to swing time, swing velocity, stance time, double-limb support time and the range of motion for the hip, knee and ankle speed up or slow down, the measured distance increased or decreased and the computer control system accelerated or joint angles were assessed for at least 120 stride cycles. Further analysis was performed using Microsoft Excel and decelerated the treadmill in order to return the subject to the calibrated position. The speed of the treadmill was recorded StatView; SAS Inc., Cary, NC, USA. Swing time, stance time and double-limb support time were expressed as a Walking velocity, stride length and cadence percentage of stride. All available steps were used to calculate After a short training period of Ͻ5 min, healthy subjects and the intrasubject variability of walking velocity, stride length, all patients with stimulation on were able to perform free double support time and stride duration (which corresponds walking on the treadmill. The average walking velocity of to that of cadence) using a variation coefficient (VC) the 12 age-matched healthy subjects was 1.07 m/s with a calculated as mean stride length of 1.15 m and a mean cadence (steps/ min) of 112. The eight Parkinson's disease patients achieved VC ϭ 100 ϫ SD/mean. a mean walking velocity of 0.35 m/s with a stride length of 0.34 m and a consecutive relative increase in cadence to 122 Healthy subjects increase walking velocity by increasing in their baseline off-stimulation/off-medication condition. both cadence and stride length in a stable linear relationship.
The walking velocities of each of the eight Parkinson's As the observed changes in velocity in Parkinson's disease disease patients for all four conditions are illustrated in Fig. 1 . patients were due mainly to an increase in stride length, we Table 2 summarizes the mean values and standard calculated this contribution of stride length (C sl ) as a deviations of all gait measures for healthy subjects and the percentage of the velocity increase according to the formula patients in the different study conditions. Off-medication/ given in Ferrandez and Blin (1991) : off-stimulation, two patients were not able to walk the 120 stride cycles required for the full protocol. In this single
condition for these two patients, only walking velocity, stride where L is the stride length during walking off medication length and cadence could be assessed reliably from a few and off stimulation, ∆L is the difference between L and steps. To allow comparison between all four conditions, the the stride length in the respective remaining condition (on mean values of the remaining measures are given in Table 2 medication or on stimulation or both), D is the stride duration only for those six patients for whom all data for all four during walking off medication and off stimulation, and ∆D conditions were available. The two patients who were is the difference between D and the respective remaining virtually unable to walk off-stimulation/off-medication condition. For all gait measurements, mean values were reached values similar to those for the other six patients in generated for each subject and each condition. Subject means the three remaining conditions and are therefore not shown were then used to generate group means and differences separately. For all eight patients, STN stimulation alone between therapeutic conditions. Each patient served as his increased the mean walking velocity considerably from 0.35 own control using the -stim/-dopa condition as the baseline.
to 0.96 m/s, which is almost in the range of healthy subjects. To assess the effect of STN stimulation alone, the baseline In most patients, this increase was achieved solely by an values (-stim/-dopa) were subtracted from the ϩstim/-dopa increase of almost threefold in stride length from 0.34 to values for each patient, and the mean differences and their 0.99 m, whereas there was a slight decrease in cadence from 95% confidence intervals were calculated. Corresponding 122 to 118. L-Dopa alone had an effect similar to that of differences and confidence intervals were calculated to assess STN stimulation alone, with an increase in walking velocity the effects of L-dopa for the control subjects in Fig. 2 . As can be seen in stimulation alone, the score improved to 7.4 Ϯ 2.7, which is the figure, the patients changed their stride length-cadence similar to the preoperative value of 7.6 Ϯ 2.6 in the on stage.
relationship so that it came within the range of the control With L-dopa alone, the value was 13.6 Ϯ 6.9. The combination subjects. The calculated contribution (mean Ϯ standard of stimulation and L-dopa further improved the UPDRS deviation) of stride length (C sl ) to the increase in walking motor score in all patients to 4.1 Ϯ 1.8. The Tinetti gait velocity was 106 Ϯ 22% for STN stimulation, 105 Ϯ 25% score, which assesses gait clinically on a scale from 0 to for L-dopa treatment and 101 Ϯ 10% for the combination of 12, changed dramatically: off-stimulation/off-medication the both treatments. Values above 100% are explained by a value (mean Ϯ SD) was 5.6 Ϯ 2.7, whereas it was at its decrease in the mean cadence despite an increase in walking maximum value of 12 in all but two patients during all velocity. Thus, like L-dopa, STN stimulation is highly effective in increasing stride length. therapeutic conditions. To illustrate the amounts of change induced by stimulation Additional effects of either stimulation or L-dopa are shown in Table 3D -E. It should be noted that the data for the effect and L-dopa, the mean differences between the three therapeutic conditions and the baseline (-stim/-dopa) are of adding STN stimulation to L-dopa treatment (Table 3D , difference ϩstim/ϩdopa versus -stim/ϩdopa) suggest a mild given in Table 3A -C. Absolute values and the differences as percentages of the baseline are shown together with the 95% additional effect, whereas the confidence intervals for the effect of adding L-dopa treatment to stimulation always confidence intervals. When they do not include zero, the data are set in bold type. The results for STN stimulation alone include zero (Table 3E , difference ϩstim/ϩdopa versus ϩstim/-dopa). This reflects the fact that all patients but one were similar to those for L-dopa alone. The combined effect was more pronounced than that of either treatment alone.
showed an additional effect of stimulation, whereas only three out of eight patients showed an additional improvement the stride cycle are illustrated for a representative patient in Fig. 3 . Each line represents the mean value of~120 strides. with L-dopa, to a walking velocity that was considerably higher than with STN stimulation alone (Patients 1, 5 and There was a marked increase in the range of motion for all joints in all therapeutic conditions towards the pattern of 7). As can be seen in Fig. 1 , these three patients were also the best responders to L-dopa and showed the smallest effects healthy control subjects. STN stimulation reduced intrasubject variability, as of STN stimulation alone, and consequently the highest additional effects of L-dopa (Table 1 and Fig. 1) . Also, the expressed by the decreases of~50% in mean variation coefficients for velocity, stride length and cadence. Again, chronic use of L-dopa after surgery was greatest in Patients 1 and 7, who received a daily dose of 600 and 450 mg, the extent of improvement was similar for L-dopa. The combination of stimulation and L-dopa further decreased respectively. The three best responders to STN stimulation (Patients 2, 3 and 4) did not require any L-dopa to reach a variability to the value for healthy subjects ( Table 2 ). The variability of the double-limb support time was less disturbed walking velocity similar to that of healthy subjects and they did not show better responses to L-dopa than the remaining than in healthy subjects and therefore showed only moderate changes. The mean differences between the three therapeutic patients. Patients 2 and 4 did not use any L-dopa after implantation. Thus, the chronic dose of L-dopa after surgery conditions and the baseline, together with their respective 95% confidence intervals (Table 3A- C), clearly demonstrate seems to depend on the improvement resulting from STN stimulation alone. There was no correlation between the that STN stimulation and L-dopa induced general improvements in gait measures that were similar in extent. general improvement after stimulation and the effect on gait.
The best results were obtained by a combination of both treatments, with which the patients reached the level seen in the healthy subjects, although the difference between Stance and swing phase, joint movements and stimulation alone and stimulation with L-dopa suggests that intrasubject variability not all patients require additional L-dopa (Table 3E ). With STN stimulation or L-dopa treatment, only slight changes were seen in cadence, whereas the other kinematic measures showed a twofold increase. Other kinematic measures changed secondarily to the increases in walking
Discussion
In the present study, STN stimulation induced an almost velocity and stride length. The clear reduction in the time spent in double support and the increase in the time spent in threefold increase in walking velocity by increasing stride length, while cadence was virtually unchanged. Walking at swing were explained sufficiently by the higher walking velocities in the therapeutic conditions. Swing velocity and the same velocity, patients with Parkinson's disease make shorter strides than normal subjects (Morris et al., 1998) . the range of motion of the major leg joints also increased considerably for all treatment conditions ( Table 2 ). The However, cadence regulation in patients with Parkinson's disease is considered to be nearly normal as it does not differ changes in the range of motion of the leg joints throughout from that seen in control subjects during natural walking to the increase in stride length (Elble et al., 1991) . A low degree of variability in gait measures indicates high precision (Ferrandez and Blin, 1991) . There is a close link between walking velocity and kinematic measures that improve with of the locomotor movement. According to Gabell and Nayak, the variabilities of stride length and cadence are related to STN stimulation and a consistent inverse relationship has been demonstrated between velocity and double-limb support gait patterning mechanisms and must be distinguished from the variability of the double-limb support time, which, they time, i.e. the time spent with both feet on the ground (Blin et al., 1991; Elble et al., 1991) . Regarding the minimal suggest, may be related to balance control mechanisms (Gabell and Nayak, 1984) . In our study, the variabilities of differences in cadence, most of the changes we observed with STN stimulation in double support time, swing phase, stride length and cadence were clearly increased in Parkinson's disease patients compared with control subjects. swing velocity and joint angle movements can be attributed Fig. 3 Average joint movements during the stride cycle of a single subject (Patient 4, mean of 120 strides) in the three therapeutic conditions and of a healthy control subject. The thin line represents the baseline condition (-stim/-dopa) and the thick lines represent the respective therapeutic conditions. An increase in angle indicates extension for hip and knee movements, and plantarflexion for the ankle movements. To allow comparison of joint movements at different velocities and stride durations, all strides were normalized. Heel contact corresponds to 0 and 100% of the stride cycle. V ϭ velocity.
Both measures improved considerably with STN stimulation, cadence. Laitinen found an increase in walking velocity of whereas the variability of double-limb support time was less 29% after unilateral pallidotomy (Laitinen, 1994) . After increased and consequently showed a smaller change. The bilateral posteroventral pallidotomy, Siegel and Metman decrease in variability measures related to gait patterning found a twofold increase in walking velocity (Siegel and mechanisms with STN stimulation indicates an increase in Metman, 2000) . About 80% of this increase was calculated the stability of the walking pattern. Regarding the different to be due to changed stride length. In two preliminary reports, gait measures, STN stimulation induced changes towards a much weaker effects were described for chronic stimulation normal gait pattern.
of the internal globus pallidus (GPi). After unilateral GPi stimulation, Melnick and colleagues found a velocity increase of 10-20% and no change in cadence (Melnick et al., 2000) .
Comparison between STN stimulation, L-dopa
After bilateral GPi stimulation, Allert and colleagues reported a velocity increase of~50% (Allert et al., 2000) ; as far as treatment and other surgical procedures can be judged from the data given,~80% of this increase We found similar results with almost identical mean values was due to the increase in stride length. For a group of for a suprathreshold dose of L-dopa and STN stimulation.
Parkinson's disease patients receiving bilateral STN The combination of both treatments further improved the stimulation, Allert and colleagues reported an improvement gait measures. This suggests a synergistic effect, which will in walking velocity of 120% (Allert et al., 2000) . This be discussed below. Blin and colleagues and O'Sullivan and improvement was due mainly to an increase in stride length, colleagues reported a 30% increase in walking velocity after but the authors attributed~10% of the improvement to an administration of 250 mg L-dopa (Blin et al., 1991 ; O'Sullivan increase in cadence. Although detailed data from these studies et al., 1998) . This effect is much smaller than in the present study. In line with our findings, they reported an unchanged are not available yet, this may point to a better efficacy of STN stimulation compared with other neurosurgical treatment effect could have contributed to the changes observed after administration of L-dopa. Taking account of our study design, options with respect to gait. Although relevant changes in cadence are suggested to be present after lesions or bilateral we can conclude that STN stimulation is at least as effective in improving gait as a suprathreshold dose of L-dopa, and is stimulation of the GPi, cadence is not affected by L-dopa or STN stimulation. An alternative explanation for these changes probably more effective. The effects of L-dopa we found were much stronger than those reported by other groups in cadence may be that the Parkinson's disease patients in these GPi studies were walking comparatively slowly and (Blin et al., 1991; O'Sullivan et al., 1998) . Possible reasons for this difference in effectiveness may be the abovetherefore were not yet at the break point of their linear cadence-stride length relationship (Morris et al., 1998) .
mentioned overestimation of the effect of L-dopa in the present study and the fact that we used a suprathreshold dose Consequently, some of the increase in velocity could still have been achieved by an increase in cadence without a of L-dopa. Furthermore, one of our inclusion criteria for the implantation of STN stimulation electrodes was a good consecutive decrease in stride length, as stride length does decrease (with increasing cadence) only beyond the break response to L-dopa. Finally, our patients were considerably younger than the populations taking part in other studies, in point. This cannot be judged from the abstracts cited above as not all the data required are given.
which the mean age was usually above 60 years, so that in our population less physical restraint could be expected.
The contribution of stride length depends on the Do STN stimulation and L-dopa have strategy used to increase walking velocity synergistic effects on gait?
In Parkinson's disease, different strategies can be used to Bejjani and colleagues used the UPDRS motor score in 10 increase walking velocity. A voluntary increase from a Parkinson's disease patients, and suggested a synergistic comfortable to a fast walking velocity in Parkinson's disease effect of STN stimulation and L-dopa for axial parkinsonian is achieved by increasing both stride length and cadence, symptoms (Bejjani et al., 2000) . For the gait subscore, they provided the patient is not yet walking at his maximum stride found no significant additional effect of the combination. length, i.e. if he is below the break point of his individual However, gait in the UPDRS subscore is assessed from 0 to linear stride length-cadence relationship. Ferrandez and Blin 4, which might not be sensitive enough. In the present study, reported that, without L-dopa, changes in stride length all patients except one showed additional improvement with contributed 58% to a voluntary velocity increase from a the combination of treatments compared with a suprathreshold comfortable speed to fast walking (Ferrandez and Blin, 1991) .
dose of L-dopa alone. Taking into account the overestimation With L-dopa, stride length contributed 34% to a similar of the effect of L-dopa compared with STN stimulation in voluntary increase in velocity. When the subject was walking our study, this may point to a synergistic effect. Furthermore, at a comfortable speed, stride length contributed 91% to the our results indicate that the effect of STN stimulation on gait L-dopa-related increase in velocity. For the fast walking is not necessarily closely related to the effect of L-dopa. The velocity, the contribution of stride length to the L-dopathree best responders to STN stimulation alone did not show related increase in velocity was 76%. Again, it has to be better responses to L-dopa alone than the remaining patients noted that during fast walking the patients were probably and the three worst responders to L-dopa did not show worse walking beyond their break point, so that they were unable responses to STN stimulation. In selected patients, STN to increase their stride length further. Thus, the study of stimulation alone could improve gait to the level of healthy Ferrandez and Blin does not exclude the possibility that subjects without additional L-dopa, probably because of L-dopa merely affects stride length. It can be argued that optimal electrode positioning and stimulation parameters. there is a training effect if gait testing is repeated within a
The fact that these patients were not necessarily the best few hours. In Parkinson's disease, stride length can be L-dopa responders off stimulation also supports the possibility increased to values similar to those seen in healthy subjects of a synergistic effect. In view of the pathophysiological by visual cues or attentional strategies for at least 2 h, but considerations discussed below, STN stimulation may not the gait performance reverts to baseline within 1 day. Cadence influence the same pathways as L-dopa. is not affected by these cues (Morris et al., 1996; Prokop and Berger, 1996; Azulay et al., 1999) . In view of the crossover design used in the present study, we can exclude the possibility that these strategies influence the effect seen
Pathophysiological considerations
The pathophysiology of the disturbance of stride length for STN stimulation, because starting with and without stimulation was randomized and performed on different days. regulation and its modification by dopaminergic medication or deep-brain stimulation remains speculative. The symptoms However, the effect of L-dopa may have been overestimated in our study design because all conditions including L-dopa involved in Parkinson's disease include bradykinesia, akinesia, rigidity, tremor, festinating gait and masked facies. treatment were performed after the corresponding trials without L-dopa, on the same day. The potential learning
The primary cause of these deficits is the degeneration of neurones in the substantia nigra. However, this wide range modulate stride length. It has to be kept in mind that STN stimulation and other neurosurgical interventions in of deficits appears to reflect disorders in the function of several separate pathways within the basal ganglia. As far as Parkinson's disease do not re-establish disturbed pathways directly but rather block overactive connections. The original walking is concerned, it has been proposed from animal work that the motor cortex and basal ganglia may undertake a function of these blocked pathways is therefore disturbed. The long-term effects of STN stimulation are not yet known. series of functions which provide the spatial framework necessary for the performance of sequences of voluntary
The basal ganglia play a role in allowing movement performance to shift from conscious to automatic control. In movements involved in locomotion (Garcia-Rill, 1986 ). Morris and colleagues hypothesized that there are two key dual-task conditions, Parkinson's disease patients also show a decline in walking performance if they have to perform a roles of the basal ganglia in motor control. First, they provide a phasic cue to the supplementary motor area that is timed second task at the same time, such as reciting sentences (Morris et al., 1996) . Future studies with STN should to terminate set-related activity in this area; therefore, they play a role in the maintenance of adequate movement be directed to revealing possible deficits induced by STN stimulation. It would be of interest to discover whether, in preparation for submovements performed in a sequence. Secondly, the basal ganglia contribute to motor set for whole such dual-task conditions, Parkinson's disease patients behave differently with STN stimulation than with L-dopa treatment. movement sequences and the absence of their contribution may lead to inadequate gain in motor execution mechanisms, This information may shed light not only on locomotor mechanisms. which could result in the underscaling of successive steps during gait (Morris et al., 1996) . The fact that stride length
In conclusion, the results presented here demonstrate that chronic bilateral STN stimulation improved gait in a manner responds to attentional strategies indicates that stride length deficits in Parkinson's disease relate to problems in motor similar to L-dopa, by increasing stride length while cadence is unchanged. Excursion of the lower extremity joints in the set rather than a deficit in the internal cueing of human locomotion (Morris et al., 1996) . The existence of spinal sagittal plane also increased to normal values. Measurements associated with the timing of gait including the duration of locomotion oscillators also in humans has been deduced from studies in paraplegic patients (Dietz et al., 1994) . The the subphases were unchanged when the increase in stride length and velocity was taken into account. The present pedunculopontine nucleus (PPN) as a site of termination for basal ganglia outputs was proposed to be equivalent to the results confirm that locomotion disorders in Parkinson's disease affect mechanisms involved in the control of mesencephalic locomotor region as the area that modulates spinal locomotion oscillators. It was suggested that the amplitude rather than rhythmicity. The gait measures obtained with STN stimulation alone are in the range of control descending output of the PPN is cholinergic and may be under GABAergic control, which, in turn, may be under subjects. Thus, chronic STN stimulation is effective in improving Parkinsonian gait and in some patients no subthalamic influence (Garcia-Rill, 1986) . It was argued that afferents to the PPN from the motor cortex and the basal additional L-dopa is required. ganglia are disturbed in Parkinson's disease, and lack of regulation is then reflected in an inability to start or stop locomotion, whereas the stepping mechanism as such is not
